ondansetron has been researched along with Syndrome in 10 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Syndrome: A characteristic symptom complex.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We randomized cannabis users with active emesis to either haloperidol (with a nested randomization to either 0." | 9.41 | Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. ( Crawford, FM; Day, AG; Forrester, S; Hall, AK; Ruberto, AJ; Sivilotti, MLA, 2021) |
| "We randomized cannabis users with active emesis to either haloperidol (with a nested randomization to either 0." | 5.41 | Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. ( Crawford, FM; Day, AG; Forrester, S; Hall, AK; Ruberto, AJ; Sivilotti, MLA, 2021) |
| " It is showed that the use of 100 mg of ladasten, 16 mg of ondansetron orally per day and 50 mg of agomelatine per night is more effective in therapy for fatigue/weakness syndrome in incurable cancer patients compared to standard therapy." | 5.20 | [Optimization of pharmacological therapy for weakness syndrome in incurable patients]. ( Glushchenko, VA; Karitsky, AP; Kvashnin, AV; Rozengard, SA; Ryazankina, AA, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Villedieu, E | 1 |
| Robinson, W | 1 |
| Shales, C | 1 |
| Na, S | 1 |
| Jung, DE | 1 |
| Hwang, E | 1 |
| Kim, T | 1 |
| Ruberto, AJ | 2 |
| Sivilotti, MLA | 2 |
| Forrester, S | 1 |
| Hall, AK | 2 |
| Crawford, FM | 2 |
| Day, AG | 1 |
| Ryazankina, AA | 1 |
| Rozengard, SA | 1 |
| Glushchenko, VA | 1 |
| Karitsky, AP | 1 |
| Kvashnin, AV | 1 |
| Simonetto, M | 1 |
| Ferigo, L | 1 |
| Zanet, L | 1 |
| Capus, L | 1 |
| Antonutti, L | 1 |
| Zorzon, M | 1 |
| Pizzolato, G | 1 |
| Nevins, M | 1 |
| Thomas, A | 1 |
| Walker-Smith, JA | 1 |
| Fennig, S | 2 |
| Nielsen, OH | 1 |
| Hvid-Jacobsen, K | 1 |
| Lund, P | 1 |
| Langholz, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome[NCT05244460] | Phase 3 | 45 participants (Anticipated) | Interventional | 2021-12-02 | Recruiting | ||
| Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized Controlled Trial[NCT03056482] | Phase 4 | 33 participants (Actual) | Interventional | 2017-05-21 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for ondansetron and Syndrome
| Article | Year |
|---|---|
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
[Optimization of pharmacological therapy for weakness syndrome in incurable patients].
Topics: Acetamides; Adamantane; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2015 |
Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome.
Topics: Adult; Double-Blind Method; Female; Gastric Emptying; Humans; Imidazoles; Male; Middle Aged; Nausea; | 1990 |
7 other studies available for ondansetron and Syndrome
| Article | Year |
|---|---|
Suspected Obstructive Sleep Apnea Successfully Treated with Ondansetron in a Pug.
Topics: Airway Obstruction; Animals; Craniosynostoses; Dog Diseases; Dogs; Ondansetron; Sleep Apnea, Obstruc | 2022 |
Area postrema syndrome caused by medullary infarction.
Topics: Area Postrema; Female; Humans; Infarction; Metoclopramide; Nausea; Ondansetron; Syndrome; Vomiting | 2022 |
Topics: Cannabis; Haloperidol; Humans; Ondansetron; Syndrome; Vomiting | 2021 |
Acute Akinesia, an unusual complication in Parkinson's Disease: a case report.
Topics: Acute Disease; Aged; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Creatine Kinase; Dis | 2008 |
Charles Bonnet syndrome.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Female; Hallucinations; Humans; Ondansetron; Syndrome | 1997 |
Cyclical vomiting syndrome.
Topics: Antiemetics; Child; Female; Humans; Ondansetron; Periodicity; Syndrome; Vomiting | 1998 |
Cyclic vomiting syndrome: role of a psychiatric inpatient unit in a general children's hospital.
Topics: Antiemetics; Child, Preschool; Combined Modality Therapy; Family Therapy; Female; Hospitals, Pediatr | 1999 |